Stromelysin 3 (ST3) is a matrix metalloprotease (MMP) expressed in fibroblast-like cells of most human invasive carcinomas. In this investigation, ST3 was measured by semiquantitative immunohistochemistry in I I I primary breast cancers. ST3 levels showed no correlation with tumor size, axillary-nod
High levels of TIMP-2 correlate with adverse prognosis in breast cancer
✍ Scribed by A. Remacle; K. McCarthy; A. Noël; T. Maguire; E. McDermott; N. O'Higgins; J.M. Foidart; M.J. Duffy*
- Publisher
- John Wiley and Sons
- Year
- 2000
- Tongue
- French
- Weight
- 77 KB
- Volume
- 89
- Category
- Article
- ISSN
- 0020-7136
No coin nor oath required. For personal study only.
✦ Synopsis
TIMP-2 is an endogenous inhibitor of MMPs. Most data from model systems suggest that high levels of this inhibitor prevent metastasis. In human breast cancers, however, we show that high levels of TIMP-2 correlate with both shortened disease-free interval and overall survival. In primary breast cancers, TIMP-2 levels showed no significant relationship with either tumor size or axillary node status but correlated inversely with estrogen receptor levels. TIMP-2 levels also correlated significantly with those for TIMP-1. We conclude that high levels of endogenous TIMP-2, like other protease inhibitors such as PAI-1 and TIMP-1, correlate with progression of human breast cancer.
📜 SIMILAR VOLUMES
CD105 (endoglin), a receptor for transforming growth factor (TGF) 1 and 3 in vascular endothelial cells, is highly up-regulated in blood vessels of tissues where neovascularisation occurs. It modulates endothelial-mesenchymal signalling and is essential for angiogenesis. Indeed, CD105 knockout mic
Studies from model systems suggest that matrix metalloproteinases (MMPs) are causally involved in tumor progression while tissue inhibitors of MMPs (TIMPs) prevent this progression. Here, we show that concentrations of TIMP-1 are significantly higher in breast carcinomas than in fibroadenomas. In pr
## Abstract The relative ability of the antiestrogen, tamoxifen, and its monohydroxy and desmethyl metabolites to displace tritiated estradiol from estrogen receptors isolated from human breast carcinoma was determined. 4‐Hydroxytamoxifen binds to the estrogen receptor with affinity equal to estrad